Entera Bio (NASDAQ:ENTX) Posts Earnings Results, Hits Expectations

Entera Bio (NASDAQ:ENTX) issued its quarterly earnings data on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06), Zacks reports. The company had revenue of $0.06 million for the quarter.

Entera Bio Trading Down 2.5 %

Shares of ENTX traded down $0.04 during mid-day trading on Monday, reaching $1.56. 44,502 shares of the stock traded hands, compared to its average volume of 152,617. The company has a market cap of $55.82 million, a price-to-earnings ratio of -5.71 and a beta of 1.60. Entera Bio has a 1 year low of $0.52 and a 1 year high of $3.35. The firm has a fifty day moving average price of $1.85 and a 200 day moving average price of $1.76.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Entera Bio in a report on Monday.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.